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Abstract Steroid withdrawal (SW) after paediatric renal
transplantation (RTPL) is controversial. Selective late SW
has been performed in our unit since 1995. The safety and
effects of SW were analysed retrospectively in 47 patients
undergoing RTPL between 1995 and 2004. Initial immu-
nosuppression consisted of cyclosporine A, azathioprine or
mycophenolate mofetil and steroids. Criteria for SW were:
(1) stable renal function, (2) time interval after RTPL ≥
1 year, (3) no rejection or time interval after last rejection ≥
1 year and (4) good compliance. SW was performed in 30
patients at an age of 13.5 years (range 4.5–18.5) and
2.2 years (range 1–6.6) after RTPL. After SW, one patient
experienced a steroid-sensitive rejection. Follow-up after
SW (1.3 year; range 0.25–7.5) showed maintained renal
function: glomerular filtration rate at SW and currently was
82 (65–128) and 82 (42–115) ml/min per 1.73 m2, respec-
tively. The number of patients on antihypertensive treatment
did not significantly change (at SW: n=15; currently: n=11).
Height and body mass index (BMI) remained stable: Median
standard deviation score (SDS) for height/BMI at SW and
currently was −1.1/0.2 and −0.8/0.1, respectively. Selective
late SW was safe regarding renal function and had no
significant effect on blood pressure and growth.
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Introduction
Immunosuppressive therapy after paediatric renal transplan-
tation (RTPL) traditionally included glucocorticosteroids.
The use of steroids after RTPL is associated with significant
morbidity, including body disfigurement, growth retarda-
tion and osseous and cardiovascular and metabolic compli-
cations [1–3]. Protocols with steroid withdrawal (SW) either
early (5 days to 12 months) [4–7] or late (≥12 months)
after RTPL [8, 9], or even steroid-free protocols [10, 11]
have been proposed. These protocols included induction
therapy with thymoglobulin or specific interleukin (IL)-2
receptor blockers [4–8, 11] and/or were tacrolimus (Tac)
based [4, 5, 7, 8, 10, 11]. So far, only one study has reported
successful SW in paediatric patients receiving cyclosporine
A (CyA) maintenance immunosuppression without induction
therapy [9].
However, the safety of SW has been questioned in adult
[12] and paediatric recipients [13] because of increased risk
of acute rejection and graft loss after SW. The benefit of
SW on growth (i.e. catch-up growth) and body mass index
(BMI) is predominantly observed in prepubertal children
[5, 9]. Thus, no consensus has been reached in the paediatric
community concerning steroid elimination [14] or preserva-
tion [15] after renal RTPL.
Selective late SW after RTPL was introduced at the
University Children’s Hospital Zurich in 1995. A retro-
spective study was performed to analyse the safety of SW
in a CyA-based immunosuppressive regimen concerning
graft function and risk of rejection. In addition, the effect of
SW on blood pressure and growth was examined.
Patients and methods
Patients
Forty-seven of 56 paediatric patients undergoing their first
RTPL in Zurich between 1995 and 2004 could be followed.
Eight adolescents had been transferred at or early after
RTPL to an adult centre; one patient had died of an
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associated cardiac disease 4 months after RTPL. The un-
derlying diseases were inherited, congenital or acquired in
19, 17 and 11 patients, respectively. This study was part of
the regular audit and quality assessment programme of the
unit. Written informed consent was obtained from the
parents and adolescent patients before RTPL.
Immunosuppression
Initial immunosuppression consisted of CyA (aiming at
trough levels of 180–250 ng/ml for the first 6 months and
80–120 ng/ml thereafter), azathioprine (n=7; 1 mg/kg per
day) until 1997 or mycophenolate mofetil (MMF) (n=40;
1200 mg/m2 body surface area per day) since 1998, and
prednisone (initial dosage of 1 mg/kg per day). Six patients
had induction treatment with basiliximab 2 h before and
4 days after RTPL (body weight <35 kg: 10 mg per dose;
body weight >35 kg: 20 mg per dose) as part of a multicenter
trial [16]. Other T-lymphocyte-depleting agents were not used.
Maintenance immunosuppression was switched from
CyA to Tac in 12 out of 47 patients due to biopsy-proven
steroid-resistant acute rejection (n=10 on MMF; n=2 on
azathioprine) and in one girl with hypertrichosis. MMF
dosage was reduced in children on Tac to 900 mg/m2 body
surface area per day. MMF was replaced by azathioprine in
six children (chronic diarrhoea: n=4; recurring leucopenia:
n=1; chronic abdominal pain: n=1) without effect on graft
function. Biopsy-proven acute rejection was treated with
intravenous methylprednisone pulses (1 g/1.73 m2 body
surface per day) on days 1–3. If plasma creatinine did not
decrease, steroid pulses were repeated on days 5–7. If
plasma creatinine still remained elevated, the rejection was
defined as steroid resistant, and maintenance immunosup-
pression was switched from CyA to Tac aiming at a trough
level of 10–15 μg/l for 1 month and 4–8 μg/l thereafter.
Selective late steroid withdrawal
The selective late SW protocol is summarised in Table 1.
Criteria for SW were (1) stable renal function, (2) time
interval after RTPL ≥ 1 year, (3) no rejection or time interval
since last rejection episode ≥ 1 year and (4) good compliance
based on stable drug concentrations and reliable clinic
attendance. SW was independent of prevailing steroid side
effects (e.g. cushingoid habitus, acne, arterial hypertension,
growth retardation or hyperlipidemia). If steroid dosage
reduction or SW resulted in an increase of plasma creatinine
of more than 20% of baseline, renal biopsy was performed.
Clinical evaluation
Renal function was assessed as creatinine and glomerular
filtration rate (GFR: ml/min per 1.73 m2 body surface area)
calculated by the Schwartz formula with a k-factor of 40 based
on local comparison with Cr-ethylenediaminetetraacetate
(EDTA) clearance measurements [17]. Casual blood pressure
was measured in the sitting position aiming at <95th centile
of systolic blood pressure [18] and was indexed to the 95th
centile (i.e. measured systolic/diastolic blood pressure divided
by the age-, sex- and height-specific 95th centile for systolic/
diastolic blood pressure) [19]. Antihypertensive treatment
included β-blockers (atenolol), calcium-channel blockers
(nifedipine) and angiotensin-converting enzyme (ACE) inhib-
itors (enalapril). Height, weight and BMI (BMI; kg/m2) were
correlated to normative Swiss data [20]. Serum cholesterol
was measured before and after SW.
Statistical analysis
Statistical analysis was performed using the SPSS 11.0 for
windows. Analysis of variance (ANOVA) on repeated
measurements was used to detect changes of clinical and
laboratory parameters over time. Proportions between groups
were compared by Fisher’s exact test. A p value<0.05 was
considered statistically significant.
Results
Steroid withdrawal
Patient and graft survival was 100%. Criteria for SW were
fulfilled by 31 (66%) of 47 patients. SW was performed in
30 patients at the median age of 13.5 years (range 4.5–18.5)
and 2.2 years (range 1–6.6) after RTPL. Before SW, nine
patients experienced 11 biopsy-proven acute rejections, all
within 2 months after RTPL; five patients were switched to
Tac due to steroid-resistant rejection (n=3 on MMF; n=2
on azathioprine).
SW was successful in 29 out of 30 children (Table 2).
Only one girl developed an acute rejection episode 2 weeks
after SW; steroids were restarted and plasma creatinine
returned to baseline. Follow-up between SW and the most
recent evaluation was median 1.3 year (range 0.25–7.5). An
adolescent boy experienced an acute steroid-sensitive
rejection 3.3 years after SW due to noncompliance. CyA
and Tac trough levels were 125±20.5 ng/ml and 8.5±
3.3 μg/l, respectively 1 year after RTPL and 100±22.5 ng/ml
and 5.8±0.9 μg/l, respectively 1 year after SW.
Renal function, blood pressure and growth
Renal function remained stable throughout the entire
observation period (Table 3; Fig. 1). There was no
significant difference in blood pressure before and after
SW (Table 3), but antihypertensive medication could be
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stopped in four out of 15 patients. Height increased slightly
but not significantly during the first year after RTPL and
remained stable thereafter. BMI did not change throughout
the entire period (Table 3). At the most recent examination,
there was no significant difference between the height,
assessed as standard deviation score (SDS), of prepubertal
children <13 years (n=13; median SDS −1.1; range −2.1 to
+1.2) and children >13 years (n=16; median SDS −0.75;
range −2.9 to +1.8). Three patients in the SW group had
significant proteinuria (IgA nephropathy n=2, cystinosis
n=1), but all patients had good graft function.
Extrarenal complications
No patient suffered from bone disease (i.e. fracture, epi-
physiolysis, aseptic necrosis), and there was no clinical
evidence of eye disease (i.e. cataract, visual acuity). There
was no significant difference in serum cholesterol levels 1
year before SW (4.7±1.5 mmol/l) and 2 years after SW
(4.6±1.0 mmol/l). One boy suffered from Hodgkin’s
disease at the age of 12 years and 3.3 years after RTPL;
his immunosuppression therapy consisted of CyA, MMF
and low-dose alternate-day prednisone. After successful
cytostatic therapy, the boy is in remission with good graft
function off steroids.
Patients maintained on steroids
Seventeen patients were maintained on steroids. Only one
patient, fulfilling all criteria and eligible for SW, was
maintained on steroids, as parents did not give consent for
SW. This patient was the brother of the above-mentioned
girl with acute rejection after SW. Eight patients had so far
not yet fulfilled the criteria for SW (time interval after
RTPL ≤1 year: n=4; time interval since last rejection
≤1 year: n=4). Eight further patients were still on steroids
for the following reasons: repeated urinary tract infections
with transient rise of plasma creatinine (n=3), colitis (n=1)
and recurrence of focal segmental glomerulosclerosis (n=1);
one patient each had side effects of Tac (biopsy-proven
calcineurin-inhibitor toxicity) or MMF (leucopenia) neces-
sitating dose reduction and maintenance of low-dose
alternate-day prednisone; one 17-year-old patient developed
B-cell lymphoma 5 years after RTPL, but after successful
cytostatic therapy, was in remission with impaired graft
function (plasma creatinine 220 μmol/) on low-dose alternate-
day steroids.
Table 2 Clinical data of 29 patients with successful steroid
withdrawal (SW)
Parameter Data
Sex: male/female 21/8
Renal transplantation (RTPL)
Recipient age (years) 11.2 (2–16)a
HLA mismatch (n) 3 (2–6)a
Living donor/cadaveric donor (n) 17/12
Donor age (years) 39 (2–56)a
Steroid withdrawal
Age (years) 13.5 (4.5–18.5)a
Follow-up after steroid withdrawal
Age at evaluation (years) 14.9 (5.2–23)a
Time after RTPL (years) 4.7 (1.0–8.7)a
Time after SW (years) 1.3 (0.25–7.5)a
Current immunosuppression
Cyclosporine A (CyA) and
mycophenolate mofetil (MMF)
11
CyA and azathioprine 10
Tacrolimus (Tac) and MMF 6
Tac and azathioprine 2
Induction with basiliximab 4
aMedian (range)
Table 1 Protocol of selective
late steroid withdrawal Months after renal transplantation Prednisone dosage
1 1 mg/kg per day (maximal dose 75 mg)
→ continuous, weekly tapering
2 0.5 mg/kg per day
→ continuous, weekly tapering
3 0.1 mg/kg per day
→ continuous tapering to minimal dose of 5 mg
7–12 10 mg/m2 on alternate day (minimal 10 mg; maximal 20 mg)
→ continuous slow tapering to minimal dose of 2.5 mg
12 Steroid withdrawal if:
- stable renal function
- RTPL ≥1 year
- last rejection episode ≥ 1 year
- good compliance
Early follow-up after SW Outpatient consultations: 1, 3, 5 and 9 weeks after SW
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Discussion
Late selective SW was safe in children undergoing their
first RTPL on a CyA-based immunosuppressive regimen.
Two thirds of the patients fulfilled the restrictive criteria for
SW, and all eligible patients except one underwent SW.
Slow steroid tapering and late SW, i.e. >12 months after
RTPL, was successful in 29 out of 30 children, with
maintained graft function. Only one patient experienced a
steroid-sensitive acute rejection episode immediately after
SW. As safety was the main concern, both parents (and
patients) and physicians were rather cautious, and steroid
tapering was often delayed compared with the protocol, with
subsequent postponement of SW. Thus, the observation
period after SW was limited, with a range of 0.25–7.7 years.
There was no significant effect of SW on blood pressure,
height and BMI. The lower immunosuppression following
SW might have been compensated in part in patients on
MMF, as steroids interfere with MMF bioavailability and SW
results in higher MMF exposure [21]. However, one third of
our patients with successful SW were on azathioprine.
These findings are consistent with a recent report by
Höcker al. of successful late SW after RTPL in 20 children
receiving a CyA-based regimen, with an observation period
of 2.1–6.3 years [9]. However, there was a major method-
ological difference compared with our protocol: indications
for SW were limited to steroid side effects, and the decision
for SW was made on an individual basis by the covering
physician or on patient demand [9]. In contrast, SW in our
unit followed criteria applicable to all patients. In fact, all
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Fig. 1 Plasma creatinine (−)
and glomerular filtration rate
(GFR; ∙) after renal transplan-
tation (RTPL) before and
after steroid withdrawal (SW),
year (y)
Table 3 Glomerular filtration rate (GFR), patients on antihypertensive treatment (AT), casual systolic (SBP) and casual diastolic (DBP) blood
pressure (also given as indexed blood pressure), height and body mass index (BMI) in 29 patients with steroid withdrawal (SW)
Time period GFRa ATb SBP DBP Heighta BMIa
ml/min per
1.73 m2
n (%) Casual indexed Casual indexed Standard deviation score (median, range)
RTPL+1 month 86 (71–132) 21 (72%) – – −1.6 (−3.0c to +0.6) 0.2 (−3.0 to +2.8)
– – −1.5 (−2.1 to −0.2)d
RTPL+1 year 86 (53–125) 18 (62%) 118±9.9
0.93±0.08
72±9.9
0.87±0.12
−0.9 (−2.6c to +1.5) 0.14 (−2.8 to +4.0)
−0.7 (−1.4 to +0.8)d
SW 82 (65–128) 15 (52%) 118±10.7 71±9.2 −1.1 (−4.0c to +1.8) 0.2 (−2.2 to +1.7)
0.94±0.07 0.86±0.13 −1.1 (−2.0 to +1.1)d
SW+3 months 86 (56–127) 13 (45%) 117±11.2 70±10.6 −1.0 (−3.9c to +1.8) 0.2 (−2.0 to +1.9)
0.93±0.08 0.86±0.14 –
SW+12 months 85 (52–122) 12 (41%) 117±12.3 68±9.3 −1.0 (−4.3d to +1.6) 0.1 (−1.5 to +1.6)
0.92±0.02 0.84±0.12 –
Most recent follow-up 82 (42–115) 11 (38%) 115±11.7 68±9.7 −0.8 (−4.6c to +1.8) 0.1 (−1.7 to +1.8)
0.91±0.08 0.82±0.12 −1.1 (−2.1 to +1.2)d
a No significant difference over time, b no significant difference between blood pressure at SW and follow-up, c patient with multicentric osteolysis
type III, d prebubertal children only (n=13)
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eligible patients except one underwent SW. Successful late
SW, approximately 12 months after RTPL, has also been
reported by Jensen et al. in 17 children: All patients were on
Tac, and almost all received induction therapy [8].
To reduce the steroid burden even more, early SW
protocols have been proposed. Oberholzer et al. reported
13 children with 100% graft survival after 12 months: im-
munosuppression included a 5-day course of steroids,
induction therapy (thymoglobulin or basiliximab) and main-
tenance therapy with Tac [4]. Another centre performed SW
between 4 and 12 months after RTPL. Immunosuppression
was Tac based without induction therapy. GFR remained
stable over 3 years; but graft loss occurred in 5 children after
SW [5]. Two paediatric studies used complete steroid
avoidance protocols, with an extended course of daclizumab,
Tac and MMF demonstrating 100% graft survival and stable
renal function after 1 year [10, 11].
Other studies reported less favourable results on SW after
RTPL. A study from Japan showed acute rejection in one third
of patients after SW [6], and Klaus et al. observed a high risk
of acute rejection after SW in children [13]. A meta-analysis
in adults undergoing SW after renal transplantation showed a
low but significant risk of acute rejection after SW. But there
was no increased risk of early graft failure [12].
Taken together, major concerns regarding SW protocols
for paediatric RTPL are, firstly, the rather short observation
period of prevailing studies, and secondly, the fact that most
SW protocols used induction therapy carrying an increased
risk of posttransplant lymphoproliferative disorder (PTLD)
[8, 22]. Thus, a more individualised and selective approach
to immunosuppressive treatment has been proposed [15].
Hypertension after renal RTPL is a risk factor for graft
dysfunction [23, 24] and development of end-organ damage
including early cardiomyopathy and premature atherosclero-
sis [24]. SW has been associated with significant reduction in
blood pressure [4, 8, 9]. In our study, there was also a trend
to achieve better blood pressure control (i.e. <95th centile)
with less antihypertensive medication.
Major side effects of steroids after renal RTPL are
stunted growth, obesity and body disfigurement [1, 2].
Thus, steroid-induced side effects were the only inclusion
criteria in one SW study [9]. Significant catch-up growth
after SW was more pronounced in prepubertal compared
with pubertal children [5, 9]. In our study, height and BMI
did not change after SW. Height SDS increased slightly but
not significantly during the first year after RTPL. Aggres-
sive nutrition (via gastrostomy in younger children) and
early growth hormone therapy were apparently the main
reasons for satisfactory growth before RTPL.
Successful graft survival depends on long-term compli-
ance and drug adherence. Noncompliance is a major issue
among adolescent graft recipients [25, 26]. Adolescents are
particularly prone to noncompliance of medications, such
as steroids, [25] the side effects of which cause visible
physical and bodily changes that differentiate them from
their peers [26]. SW with consequent reduction of side
effects might have a beneficial impact on long-term compli-
ance and therefore favour graft survival.
In summary, selective late SW was safe in children after
RTPL but had no significant effect on blood pressure and
growth.
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